BOPI 05 BR/2023 REPERTOIRE NUMERIQUE 21 Fig. 1 Consulter le mémoire ________________________________________ (11) 20944 (51) A61K 31/47 (2018.01); A61P 35/00 (2018.01) ; C07D 215/233 (2018.01) (21) 1202100553 - PCT/US2019/065980 (22) 12/12/2019 (30) US n° 62/856,404 du 03/06/2019 (54) Crystalline salt forms of a kinase inhibitor. (72) DEMORIN, Frenel (US); SHAH, Khalid (US); SHAKYA, Sagar (US); JOHNSON, Courtney S. (US); BEVILL, Melanie Janelle (US) et PARENT, Stephan D. (US) (73) EXELIXIS, INC., 1851 Harbor Bay Parkway, ALAMEDA, California 94502 (US) (74) AFRIC'INTEL CONSULTING, Essos, Immeuble MAH DONG Véronique. 2nd floor B.P. 8451, YAOUNDE (CM). (57) The present invention relates to crystalline forms of salts of compound 1. Compound 1 The invention also relates to pharmaceutical compositions comprising the solid crystalline salts of compound 1. The invention further relates to methods of treating a disease, disorder, or syndrome mediated at least in part by modulating in vivo activity of a protein kinase. Consulter le mémoire ________________________________________ (11) 20945 (51) A01N 37/46 (2018.01); A01P 7/04 (2018.01); C12N 1/20 (2018.01) ; C12R 1/07 (2018.01) (21) 1202100571 - PCT/EP2020/066418 (22) 14/06/2020 (30) EP n° 19382497.6 du 14/06/2019 (54) Bacillus thuringiensis strain. (72) CABALLERO SANCHEZ, Javier (ES) (73) Bioinsectis S.L., Avda. de Pamplona, n° 123, 31192 MULTIVA, Navarra (ES) (74) SPOOR & FISHER Inc. NGWAFOR & PARTNERS Sarl, The House of Gideon, Golf/Bastos Quarters, Opposite The American Embassy, Entrance-Saint John Paul II Boulevard, P.O. Box 8211, YAOUNDE (CM).
RkJQdWJsaXNoZXIy MTM1NDc3MA==